Trial Profile
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Healthcare Products
- 26 Oct 2022 Results of post hoc analysis assessing the impact of pancrelipase delayed-release capsules on exocrine pancreatic insufficiency (EPI) symptoms as reported by patients through daily diaries presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022.
- 13 Mar 2018 New trial record
- 16 Sep 2009 Results (n=52) assessing safety and efficacy published in the Trial Registry